Citadel Advisors’s Health Assurance Acquisition Corp. Class A Common Stock HAAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-30,700
Closed -$306K 15992
2022
Q3
$306K Sell
30,700
-39,200
-56% -$390K ﹤0.01% 9539
2022
Q2
$691K Sell
69,900
-23,200
-25% -$229K ﹤0.01% 7899
2022
Q1
$917K Buy
93,100
+40,200
+76% +$394K ﹤0.01% 7917
2021
Q4
$517K Sell
52,900
-58,300
-52% -$571K ﹤0.01% 9619
2021
Q3
$1.09M Sell
111,200
-16,900
-13% -$165K ﹤0.01% 7928
2021
Q2
$1.28M Buy
128,100
+57,900
+82% +$591K ﹤0.01% 7697
2021
Q1
$717K Buy
+70,200
New +$831K ﹤0.01% 8891

Other funds holding HAAC

Citadel Advisors's HAAC Position: Q3 2022 in Review

Citadel Advisors sold out of Health Assurance Acquisition Corp. Class A Common Stock (HAAC) in Q3 2022, closing a stake of 51,200 shares — an estimated $509K sold.

Citadel Advisors first reported a position in HAAC in Q1 2021 and held it in 6 quarters. The position peaked at $1.97M in Q1 2021. 85 funds tracked by Wall St. Rank hold HAAC as of Q3 2022.

  • Citadel Advisors reported no remaining Health Assurance Acquisition Corp. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 51,200 Health Assurance Acquisition Corp. Class A Common Stock shares in Q3 2022, an estimated $509K.
  • Citadel Advisors first reported a position in Health Assurance Acquisition Corp. Class A Common Stock in Q1 2021 and held it in 6 quarters.
  • Citadel Advisors's Health Assurance Acquisition Corp. Class A Common Stock position peaked at $1.97M in Q1 2021.
  • 85 funds tracked by Wall St. Rank held Health Assurance Acquisition Corp. Class A Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.